Publications by authors named "J Alvarez Aldean"
Article Synopsis
- RSV significantly impacts infants in Spain, leading to many healthcare visits and high costs during their first RSV season.
- A decision-analytic model showed that using nirsevimab as a preventive treatment for all infants could dramatically reduce RSV-related health events and hospitalizations, compared to standard practices.
- Immunizing with nirsevimab could prevent over 97,000 outpatient visits and save about €47.8 million in healthcare costs, highlighting its potential as a cost-effective public health strategy.
Safety and tolerability of cell culture-derived and egg-derived trivalent influenza vaccines in 3 to <18-year-old children and adolescents at risk of influenza-related complications.
Javier Diez-Domingo Maurizio de Martino Jose Garcia-Sicilia Lopez Gian Vincenzo Zuccotti Giancarlo Icardi
Int J Infect Dis
August 2016
Background: This descriptive, non-comparative, phase III study evaluated the safety and tolerability of cell culture-derived (TIVc) and egg-derived (TIV) seasonal influenza vaccines in children at risk of influenza-related complications.
Methods: Four hundred and thirty subjects were randomized 2:1 to TIVc or TIV. Subjects aged 3 to <9 years received one dose (if previously vaccinated, n=89) or two doses (if not previously vaccinated, n=124) of the study vaccines; the 9 to <18-year-olds (n=213) received one dose.